Hemidesmosomal adhesion complex (HD)

The hemidesmosomal adhesion complex is a specialized multiprotein junction that anchors epithelial cells to the underlying basement membrane, primarily in the skin and mucous membranes (Walko et al., 2015, J Cell Sci). It consists of transmembrane proteins like integrin alpha-6 beta-4 and type XVII collagen (BP180), which connect the intracellular keratin intermediate filaments via plectin and BP230 to the extracellular matrix protein laminin-332 (UniProt Consortium, 2023). This complex is vital for maintaining the mechanical stability of the dermo-epidermal junction (StatPearls, 2023). In autoimmune diseases like bullous pemphigoid, the body produces autoantibodies against components of this complex, leading to subepidermal blistering (Borradori & Sonnenberg, 1999, J Invest Dermatol). Additionally, the complex plays a role in cancer progression, where its disassembly or remodeling can facilitate tumor cell invasion and metastasis (Stewart & O'Connor, 2015, Cell Adh Migr). Current therapeutic approaches largely involve immunosuppressive agents and biologics that target the inflammatory pathways responsible for damaging the complex (Moro et al., 2023, Front Med).

Other names

HemidesmosomeDermo-epidermal junction complexBasal adhesion complexType I hemidesmosomeType II hemidesmosome

Therapeutic interventions primarily focus on suppressing the autoimmune response against complex components. This includes B-cell depletion via Rituximab to reduce autoantibody production, and the use of Omalizumab or Dupilumab to inhibit IgE-mediated or Th2-driven inflammation that leads to the proteolytic degradation of the complex (Moro et al., 2023, Front Med; StatPearls, 2023).